Semaglutide vs Tirzepatide: Which Is Right for You? (2026)

01

Semaglutide vs tirzepatide at a glance

(All figures cited inline below to FDA labels + trial publications. Verify current details at time of reading.)

02

How they work: single vs dual hormone

Semaglutide mimics one gut hormone, GLP-1, which slows gastric emptying and acts on brain appetite centers so you feel full sooner and longer.

Tirzepatide does that and activates the GIP receptor — a second incretin hormone — which is thought to add to appetite and metabolic effects.

Both mechanisms are described by the FDA labels and major clinics such as Mayo Clinic.

The shared GLP-1 action is why their side-effect profiles overlap so heavily.

03

Weight loss: what the trials show

The cleanest way to compare is the trials. In STEP-1, semaglutide 2.4 mg produced a mean 14.9% weight loss over 68 weeks.

In SURMOUNT-1, tirzepatide produced 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) over 72 weeks.

Crucially, these two were finally compared head-to-head in SURMOUNT-5 (NEJM, 2025): over 72 weeks in adults with obesity but without diabetes, tirzepatide reduced body weight by −20.2% versus −13.7% for semaglutide (p<0.001).

On efficacy alone, tirzepatide won — but "more weight loss" is only one axis of a good decision.

04

Side effects and tolerability: are they different?

They share the same broad GI profile — nausea, vomiting, diarrhea, constipation — because they act on the same GLP-1 pathway.

A common assumption is that the stronger drug must be harder to tolerate, but SURMOUNT-5 found the opposite direction: GI adverse events causing discontinuation were slightly more frequent with semaglutide (5.6%) than tirzepatide (2.7%). Both carry the FDA boxed warning for thyroid C-cell tumors and the same serious risks (pancreatitis, gallbladder disease).

The biggest predictor of how you'll tolerate either drug is how quickly you escalate the dose, not which brand you pick.

For the full breakdown, see our tirzepatide side effects guide.

05

Dosing and forms

Semaglutide (Wegovy) titrates 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg in four-week steps; tirzepatide titrates 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg in four-week steps, per the FDA labels. 2.4 mg weekly is the standard maintenance dose.

A higher 7.2 mg weekly maintenance dose was approved in the EU (February 2026) and the US (March 2026, as Wegovy HD) for adults with obesity who have taken 2.4 mg for at least 4 weeks and need more weight loss; altered skin sensations (dysesthesia) were much more common at 7.2 mg (21.6% vs 0.3% on placebo in the STEP UP trial).

One practical differentiator: semaglutide has oral options — Rybelsus for type 2 diabetes and the Wegovy pill (oral semaglutide 25 mg) for weight management (approved in the US in December 2025 and the EU in July 2026) — while tirzepatide is injection only. Your first four weeks look similar on either — see our GLP-1 first-month guide.

06

Cost and access

Both are expensive without coverage, and pricing shifts frequently, so verify current numbers with your pharmacy and plan.

Access also differs by indication: Ozempic and Mounjaro are FDA-approved for type 2 diabetes, while Wegovy and Zepbound are approved for weight management — which drug your insurance will cover often hinges on that distinction and your diagnosis.

Compounded versions are no longer broadly permitted now that the shortages have resolved; only the FDA-approved brands are quality-assured.

07

Which should you choose?

Neither is universally "better." Weigh these, then decide with your prescriber:

1. Maximum weight loss is the priority → the head-to-head data favor tirzepatide.
2. You want the longest track record and established CV-benefit data → semaglutide leads here.
3. You prefer a pill over an injection → only semaglutide offers a pill (Rybelsus for T2D; the Wegovy pill for weight management).
4. Tolerability / side-effect history → individual, and driven more by titration speed than by brand.
5. Cost and insurance → coverage often follows your indication (diabetes vs obesity) and the specific brand on your formulary.
6. Availability → confirm which brands and indications are approved and stocked in your region.

08

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Depending on the study, lean (muscle and other non-fat) tissue has accounted for anywhere from about 15% to 40–60% of the weight lost on GLP-1-based therapy (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

Related articles